+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Effects of different doses of metformin treatment for 6 months on aberrant crypt foci in Chinese patients with impaired glucose tolerance



Effects of different doses of metformin treatment for 6 months on aberrant crypt foci in Chinese patients with impaired glucose tolerance



European Journal of Cancer Prevention 24(1): 27-36



This research was carried out to evaluate the chemopreventive effects of different doses of metformin treatment for 6 months on rectal aberrant crypt foci (ACF) in patients with impaired glucose tolerance (IGT). A total of 120 Chinese patients with IGT were enrolled and assigned randomly to a low-dose metformin group (n=30, metformin at 250 mg/day), a middle-dose metformin group (n=30, metformin at 500 mg/day), a high-dose metformin group (n=30, metformin at 1500 mg/day), and a control (untreated with metformin) group (n=30). Each participant was followed for 6 months by protocol, and the number of ACF per patient in the above four groups was examined by magnifying colonoscopy before, and after 3 and 6 months of, treatment. The mean ACF numbers in both the middle-dose and the high-dose metformin groups were significantly decreased at 3 as well as 6 months of treatment, whereas they did not change in the low-dose metformin and the untreated groups. In the high-dose metformin group, BMI, waist circumference, fasting plasma glucose, homeostatic model assessment of insulin resistance index, and 2-h plasma glucose were significantly decreased. However, no such change was observed in the middle-dose metformin group. Changes in the ACF number correlated positively with changes in the homeostatic model assessment of insulin resistance (r=0.273, P=0.013), BMI (r=0.241, P=0.042), and 2-h plasma glucose (r=0.252, P=0.037), respectively, in the high-dose metformin group, but no such correlation was observed in the middle-dose metformin group. Metformin suppressed ACF formation in IGT patients in a dose-dependent manner, possibly through direct and indirect (attenuating insulin resistance) mechanisms.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 052863014

Download citation: RISBibTeXText

PMID: 25162967

DOI: 10.1097/cej.0000000000000078


Related references

Overexpression of PPARdelta and cyclin D1 in dysplastic aberrant crypt foci and in adenomas, but not in hyperplastic aberrant crypt foci in Apc Min/+ mice. Toxicology Letters (Shannon) 144(Suppl 1): s122, 2003

Metabolic effects of metformin in patients with impaired glucose tolerance. Diabetic Medicine 18(7): 578-583, 2001

Effects of metformin in obese patients with impaired glucose tolerance. Diabetes/Metabolism Reviews 11(Suppl. 1): S69-S80, 1995

Metformin treatment leads to an increase in basal, but not insulin-stimulated, glucose disposal in obese patients with impaired glucose tolerance. Diabetic Medicine 16(8): 650-655, 1999

Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prevention Research 3(9): 1077-1083, 2010

Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase. Molecular Carcinogenesis 49(7): 662-671, 2010

Effects of indole-3-carbinol on immune responses, aberrant crypt foci, and colonic crypt cell proliferation in rats. Journal of Toxicology and Environmental Health. Part a 62(7): 561-573, 2001

Comment re: "Sporadic aberrant crypt foci are not a surrogate endpoint for colorectal adenoma prevention" and "Aberrant crypt foci in the adenoma prevention with celecoxib trial". Cancer Prevention Research 1(3): 215-6; Author Reply 216, 2009

Effects of metformin plus rosuvastatin on hyperandrogenism in polycystic ovary syndrome patients with hyperlipidemia and impaired glucose tolerance. Journal of Endocrinological Investigation 35(10): 905-910, 2012

Effects of impaired fasting glucose and impaired glucose tolerance on predicting incident type 2 diabetes in a Chinese population with high post-prandial glucose. Diabetes Research and Clinical Practice 66(2): 183-191, 2004

Protective effect of metformin in an aberrant crypt foci model induced by 1,2-dimethylhydrazine: Modulation of oxidative stress and inflammatory process. Molecular Carcinogenesis 56(3): 913-922, 2017

Effects of sphingomyelin on aberrant colonic crypt foci development, colon crypt cell proliferation and immune function in an aging rat tumor model. Food and Chemical Toxicology 41(4): 471-476, 2003

Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes. Hypertension Research 30(1): 23-30, 2007

Lymphocyte-suppressing, endothelial-protective and systemic anti-inflammatory effects of metformin in fenofibrate-treated patients with impaired glucose tolerance. Pharmacological Reports 65(2): 429-434, 2013

Characteristic of metformin for treatment of impaired glucose tolerance. Nihon Rinsho. Japanese Journal of Clinical Medicine 63(Suppl. 2): 433-437, 2005